Zimmer Biomet Holdings, Inc.

Equities

ZBH

US98956P1021

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 01:30:01 16/07/2024 am IST			5-day change	1st Jan Change
106.5 ^USD	-1.99%		+0.13%	-12.47%

03:54am	Osteopore Taps Zimmer Biomet as Exclusive Distributor in EMEA, APAC; Shares Jump 30%	MT
15/07	Morgan Stanley Cuts Price Target on Zimmer Biomet Holdings to $120 From $130, Maintains Equalweight Rating	MT

Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2022 Financial Results

January 09, 2023 at 08:30 pm IST

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Friday, February 3, 2023 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET.

The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call.

Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (888) 204-4368 and entering conference ID 5103691. International callers should dial +1 (323) 994-2093 and enter conference ID 5103691.

About Zimmer Biomet

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

Contact:

Keri Mattox

Tel: 703-346-3127

Email: meredith.weissman@zimmerbiomet.com

Latest news about Zimmer Biomet Holdings, Inc.

Osteopore Taps Zimmer Biomet as Exclusive Distributor in EMEA, APAC; Shares Jump 30%	07:24am	MT
Morgan Stanley Cuts Price Target on Zimmer Biomet Holdings to $120 From $130, Maintains Equalweight Rating	15/07	MT
Morgan Stanley Cuts Price Target on Zimmer Biomet Holdings to $120 From $130, Keeps Equalweight Rating	15/07	MT
Citigroup Adjusts Price Target on Zimmer Biomet to $120 From $134	11/07	MT
Citigroup Adjusts Price Target on Zimmer Biomet to $134 From $120	11/07	MT
Citigroup Adjusts Price Target on Zimmer Biomet to $120 From $134	10/07	MT
Goldman Sachs Adjusts Price Target on Zimmer Biomet Holdings to $118 From $129	10/07	MT
Stryker Corporation : Major Player in Medical Devices	06/07
Evercore ISI Adjusts Price Target on Zimmer Biomet Holdings to $115 From $130, Maintains In-Line Rating	02/07	MT
Zimmer Biomet Shares Fall Following Piper Sandler Downgrade	02/07	MT
Piper Sandler Downgrades Zimmer Biomet to Neutral From Overweight, Adjusts Price Target to $115 From $140	01/07	MT
Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors	20/06	CI
Zimmer Biomet Enters Co-Marketing Deal With RevelAi Health	12/06	MT
RevelAi Health and Zimmer Biomet Holdings, Inc. Announce Exclusive Multi-Year Co-Marketing Agreement to Advance Value-Based Care and Health Equity Through AI-Powered Technology	12/06	CI
Transcript : Zimmer Biomet Holdings, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM	11/06
Zimmer Biomet Enters Distribution Agreement with THINK Surgical to Offer TMINI Miniature Handheld Robotic System for Total Knee Arthroplasty	11/06	CI
Osteal Therapeutics, Inc. announced that it has received $50 million in funding from Zimmer Biomet Holdings, Inc., Johnson & Johnson Innovation - JJDC, Inc., HM Capital Management, LLC, GIDEON STRATEGIC PARTNERS LLC and other investors	05/06	CI
Zimmer Biomet Holdings Insider Sold Shares Worth $1,474,582, According to a Recent SEC Filing	05/06	MT
Zimmer Biomet's Limited Exposure to High-Growth Markets Spurs Revenue Concerns, UBS Says	01/06	MT
Barclays Adjusts Price Target on Zimmer Biomet to $125 From $130	31/05	MT
Barclays Adjusts Price Target on Zimmer Biomet Holdings to $125 From $130	31/05	MT
Zimmer Biomet Outlines Growth Strategy Through 2027; Board Approves $2 Billion Stock Buyback	30/05	MT
Zimmer Biomet Holdings, Inc. announces an Equity Buyback for $2,000 million worth of its shares.	30/05	CI
Transcript : Zimmer Biomet Holdings, Inc. - Analyst/Investor Day	29/05
Zimmer Biomet Holdings, Inc. authorizes a Buyback Plan.	29/05	CI

Chart Zimmer Biomet Holdings, Inc.

Duration

Period

More charts

Company Profile

Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows: - reconstruction implants (57.5%): knees replacement (58.8% of net sales), hips replacement (41.2%); - surgical products and traumatology equipment (22.1%); - dental, spinal and craniomaxillofacial implants (12.8%); - other (7.6%): primarily orthopedic surgery materials and instruments used during post-operative rehabilitation. At the end of 2021, the group had approximately 30 production sites worldwide. Net sales are distributed geographically as follows: Americas (61.3%), Europe/Middle East/Africa (21.3%) and Asia/Pacific (17.4%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

07/08/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Zimmer Biomet Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

106.5 USD

Average target price

133.5 USD

Spread / Average Target

+25.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ZIMMER BIOMET HOLDINGS, INC.	-12.47%	2.19TCr
ABBOTT LABORATORIES	-6.46%	18TCr
MEDTRONIC PLC	-6.43%	9.88TCr
BECTON, DICKINSON AND COMPANY	-7.28%	6.53TCr
HOYA CORPORATION	+15.46%	4.54TCr
DEXCOM, INC.	-8.93%	4.49TCr
CENCORA, INC.	+8.19%	4.38TCr
METTLER-TOLEDO INTERNATIONAL, INC.	+12.00%	2.9TCr
TERUMO CORPORATION	+19.39%	2.56TCr
WEST PHARMACEUTICAL SERVICES, INC.	-9.09%	2.33TCr

Other Medical Equipment, Supplies & Distribution